Search Results 301-310 of 16777 for Azlocillin

  1. Clinical trials - Oncology (Medical)

    This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

  2. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) ...

  3. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

    Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more ...

  4. Clinical and Basic Investigations into Congenital Disorders of Glycosylation

    About this study. The purpose of this study is to establish the prevalence and severity of specific morbid indicators of disease severity such as specific ...

  5. Sugar Hyperabsorption Impact on Post-Bariatric Surgery Weight Loss Outcomes in African American Patients - Mayo Clinic

    About this study. The purpose of this study is to investigate glucose and fructose absorption in enteroids from obese African American subjects before and ...

  6. Infliximab-dyyb (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Infliximab-dyyb injection is used to reduce the symptoms of moderate to severe active Crohn's disease and ulcerative colitis in adults and children who have ...

  7. Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3) - Mayo Clinic

    Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3) · Overview.

  8. A Study Of QOL With Secondary Hypogammaglobulinemia - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or without Bevacizumab, for Patients who have Stage IV Non-Squamous Non-Small Cell Lung Cancer - Mayo Clinic

    A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or without Bevacizumab, for Patients who have Stage IV Non- ...

  10. Study to Assess the Effectiveness and Safety of Bradanicline in Patients with Chronic Cough - Mayo Clinic

    The purpose of this study is to evaluate the dose-response of bradanicline in reducing awake objective cough frequency. Participation eligibility. Participant ...